Ogier advises ORI Capital on launch of its second healthcare fund

Ogier's Hong Kong team has recently advised ORI Capital on the launch of ORI Healthcare Fund II, its second healthcare-centered venture capital fund with a target close of US$400 million. The fund is expected to be double the size of ORI Healthcare Fund, which was launched in 2016.

ORI Capital was founded by Simone Song, former Head of Goldman Sachs Healthcare Investment Banking for Greater China and is a Hong Kong based investment firm focusing on the healthcare sector. It is a member of the Hong Kong Green Finance Association, and is committed to being socially impactful and contributing to the greater good. Its first fund had invested in companies such as Semma Therapeutics, Kymab, CG Oncology and the NASDAQ-listed Orchard Therapeutics.

Kate Hodson said: "It was a great pleasure to work with ORI Capital on this healthcare fund.  Venture capital plays an important role in the impact space.  With chronic diseases being on the rise, combined with longer average life expectancy, this is putting heavy burden on global healthcare systems and contributes to a demand for innovation in the healthcare sector".

The Ogier team was led by Kate Hodson, partner in Ogier's investment funds practice in Hong Kong and Head of ESG Funds for Ogier, and included Alan Wong from the Hong Kong office. The team advised ORI Capital on the Cayman law aspects of the fund launch. The Ogier team worked alongside lead counsel Cleary Gottlieb Steen & Hamilton LLP.